MSMarva Seifert

Marva Seifert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marva Seifert has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cepheid 9-gene host mRNA expression across the spectrum of Mycobacterium tuberculosis infection and disease: insights across the lifespan

    by Marva Seifert, Michael Gracia, Donald G. Catanzaro, Faiqa Rashid, Rehan R. Syed, Faisal Masood, Naomi Hillery, Alamdar Hussain, Ashley Swing, Rebecca E. Colman, et al.

  • Open Access

    Willingness to Receive Latent Tuberculosis Infection Treatment Among Migrants in Tijuana, Baja California, Mexico

    by Richard S Garfein, Marva Seifert, Daniela Abramovitz, Ietza Bojorquez-Chapela, Alicia Harvey-Vera, Jaime Sepulveda, Steffanie A Strathdee

    Over 80% of tuberculosis cases in the United States are due to reactivation of untreated latent tuberculosis infection (LTBI), most of whom were foreign born. LTBI treatment can greatly lower the risk of progression to active TB disease, and shorter treatment regimens increase the potential of migrants and other persons in vulnerable conditions, to complete treatment. We conducted across-sectional study to assess willingness to complete a one-month course of LTBI treatment among internal and international migrants living in Tijuana, BC, Mexico, and to identify factors associated with treatment unwillingness between November 2020 and April 2021. Prior to administering TB skin tests (TST), participants were asked if they would accept LTBI treatment if indicated by test results and clinical examination. Recruitment occurred in migrant shelters throughout Tijuana and at a storefront office conducting research and harm reduction services for people who use drugs. Among 595 participants, 80.4% were living in shelters, 3.5% were recruited at shelters but living independently, and 16.1% were recruited through the storefront office. Overall, 71 (11.9%) indicated that they were unwilling to take LTBI treatment and 109 (18.3%) had positive TST results. Unwillingness to take LTBI treatment was more common among participants from the storefront office compared to the shelter (64.6% vs. 1.8%, p<0.001). Since only 1.8% of shelter participants were unwilling to receive treatment, multivariable Poisson regression with robust variance estimation via GEE for identifying factors independently associated with LTBI treatment unwillingness was restricted to storefront participants. Treatment unwillingness among storefront participants was positively associated with perceiving health status as “good” or “very good” (prevalence ratio [PR]=2.37, 95% confidence interval [CI]: 1.52, 3.99) and heroin use in the past six months (PR=1.70; 95% CI: 1.33, 2.19). Unstable housing was reported as a barrier to treatment. These findings suggest that most migrants in Tijuana were willing to receive short-course LTBI treatment if indicated, yet willingness was lower among those at greatest risk of TB. Efforts to increase testing and treatment, as well as further research on overcoming barriers to treatment willingness are needed.

  • Open Access

    Comparing end-user diagnostic outputs from a commercial tNGS pipeline for Mycobacterium tuberculosis drug resistance detection

    by M. Seifert, R.E. Colman, S. Laurent, A. De la Rossa, S. Uplekar, C. Rodrigues, N. Tukvadze, S.V. Omar, A. Suresh, T.C. Rodwell

    SUMMARY: BACKGROUND: Targeted next-generation sequencing has emerged as a rapid solution for diagnosing drug-resistant TB (DR-TB) directly from clinical specimens. Updating the bioinformatics software component can lead to rapid improvements in diagnostic performance. We compared the diagnostic performance of an updated bioinformatic pipeline output to the original pipeline output for the Oxford Nanopore Technology (ONT) TB Drug Resistance Test. METHODS: A total of 721 sediment samples were evaluated for 13 anti-TB drugs using phenotypic drug susceptibility testing and whole genome sequencing. Sequencing data outputs previously analysed using the original pipeline were re-analysed using an updated pipeline and compared. RESULTS: There were no significant differences in successful sequencing results, and direct comparison of DR-TB call agreement was substantial (κ > 0.7) between the original and updated pipeline outputs. Diagnostic accuracy relative to the composite reference standard was compared, and significant ( P value < 0.05) increases in sensitivity and diagnostic yield, using the updated pipeline, were identified for streptomycin, pyrazinamide, bedaquiline, and clofazimine. CONCLUSION: Comparison of the updated pipeline to the original pipeline revealed significant improvements in diagnostic performance, demonstrating that bioinformatic enhancements alone – without wet-lab modifications – can substantially boost sensitivity and diagnostic yield for DR-TB. These findings underscore the critical role of continuous pipeline optimisation in the evolving resistance landscape to enhance real-time clinical decision-making.

  • Open Access

    Prospective Exploratory Evaluation of Cepheid Xpert Mycobacterium tuberculosis Host Response Cartridge: A Focus on Adolescents and Young Adults

    by Marva Seifert, Donald G Catanzaro, Michael Gracia, Naomi Hillery, Sabira Tahseen, Faisal Masood, Alamdar Hussain, Uzma Majeed, Rebecca E Coleman, Rehan R Syed, et al.

    Background: An accurate, rapid, non-sputum-based triage test for diagnosing tuberculosis (TB) is needed. Methods: A prospective evaluation of the Cepheid GeneXpert Mycobacterium tuberculosis Host Response cartridge (Xpert-MTB-HR), a prototype blood-based host response mRNA signature assay, among individuals presenting with TB-like symptoms was performed in Pakistan and results were compared to 3 reference standards: Xpert MTB/RIF Ultra, bacteriological confirmation (Xpert MTB/RIF Ultra and/or culture positivity), and composite clinical diagnosis (clinician diagnosis, treatment initiation, Xpert MTB/RIF Ultra, and/or culture positivity). Analyses were conducted both for the entire study cohort and separately in the adolescent and young adult cohort (aged 10–24 years). Results: A total of 497 participants, aged 6–83 years, returned valid Xpert-MTB-HR results. When a diagnostic threshold was set for a sensitivity of >90%, specificity was 32% (95% confidence interval [CI], 28%–37%) compared to Xpert MTB/RIF Ultra, 29% (95% CI, 25%–34%) compared to a bacteriological confirmation, and 22% (95% CI, 18%–26%) compared to a composite clinical diagnosis. However, when evaluating only the adolescent and young adult cohort with a diagnostic threshold set for sensitivity of >90%, specificity was 82% (95% CI, 74%–89%) compared to Xpert MTB/RIF Ultra, 84% (95% CI, 75%–90%) compared to a bacteriological confirmation, and 54% (95% CI, 44%–64%) compared to a composite clinical diagnosis. Conclusions: While the Xpert-MTB-HR does not meet World Health Organization minimum criteria in the general population, in our study it does meet the minimum sensitivity and specificity requirements for a non-sputum-based triage test among adolescents and young adults when compared to Xpert MTB/RIF Ultra or bacteriological confirmation.


  • Open Access

    Predicting stringent QuantiFERON-TB Gold Plus conversions in contacts of tuberculosis patients

    by Sheng-Wei Pan, Donald G. Catanzaro, Marva Seifert, Rehan R. Syed, Naomi Hillery, Mei-Lin Ho, Valeriu Crudu, Elena Tudor, Nelly Ciobanu, Alexandru Codreanu, et al.


  • Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort

    by Rehan R. Syed, Donald G. Catanzaro, Rebecca E. Colman, Christopher G. Cooney, Yvonne Linger, Alexander V. Kukhtin, Rebecca C. Holmberg, Ryan Norville, Valeriu Crudu, Nelly Ciobanu, et al.

    While the goal of universal drug susceptibility testing has been a key component of the WHO End TB Strategy, in practice, this remains inaccessible to many. Rapid molecular tests for tuberculosis (TB) and antituberculosis drug resistance could significantly improve access to testing.


  • Open Access

    Detecting rifampin and isoniazid resistance in Mycobacterium tuberculosis direct from patient sputum using an automated integrated system

    by Rebecca E. Colman, Christopher Hagan, Peter Chiles, Marva Seifert, Donald G. Catanzaro, Alexander V. Kukhtin, Ryan Norville, Laura Hauns, Arial Bueno, Rebecca C. Holmberg, et al.


  • Open Access

    Detection and quantification of Mycobacterium tuberculosis antigen CFP10 in serum and urine for the rapid diagnosis of active tuberculosis disease

    by Marva Seifert, Eva Vargas, Victor Ruiz-Valdepeñas Montiel, Joseph Wang, Timothy C. Rodwell, Antonino Catanzaro

    Outside of the ongoing COVID-19 pandemic, tuberculosis is the leading cause of infectious disease mortality globally. Currently, there is no commercially available point-of-care diagnostic that is rapid, inexpensive, and highly sensitive for the diagnosis of active tuberculosis disease. Here we describe the development and optimization of a novel, highly sensitive prototype bioelectronic tuberculosis antigen (BETA) assay to detect tuberculosis-specific antigen, CFP10, in small-volume serum and urine samples. In this proof-of-concept study we evaluated the performance of the BETA assay using clinical specimens collected from presumptive tuberculosis patients from three independent cohorts. Circulating CFP10 antigen was detected in ALL serum (n = 19) and urine (n = 3) samples from bacteriologically confirmed tuberculosis patients who were untreated or had less than one week of treatment at time of serum collection, successfully identifying all culture positive tuberculosis patients. No CFP10 antigen was detected in serum (n = 7) or urine (n = 6) samples from individuals who were determined to be negative for tuberculosis disease. Additionally, antigen quantification using the BETA assay of paired serum samples collected from tuberculosis patients (n = 8) both before and after treatment initiation, indicate consistently declining within-person levels of CFP10 antigen during treatment. This novel, low-cost assay demonstrates potential as a rapid, non-sputum-based, point-of-care tool for the diagnosis of tuberculosis disease.


  • Open Access

    Age and sex distribution of Mycobacterium tuberculosis infection and rifampicin resistance in Myanmar as detected by Xpert MTB/RIF

    by Marva Seifert, Hlaing Thazin Aung, Nicole Besler, Victoria Harris, Tin Tin Mar, Rebecca E. Colman, Timothy C. Rodwell, Si Thu Aung

    Background: Detection of tuberculosis disease (TB) and timely identification of Mycobacterium tuberculosis (Mtb) strains that are resistant to treatment are key to halting tuberculosis transmission, improving treatment outcomes, and reducing mortality. Methods: We used 332,657 Xpert MTB/RIF assay results, captured as part of the Myanmar Data Utilization Project, to characterize Mtb test positivity and rifampicin resistance by both age and sex, and to evaluate risk factors associated with rifampicin resistance. Results: Overall, 70% of individuals diagnosed with TB were males. Test positivity was higher among males (47%) compared to females (39%). The highest positivity by age occurred among individuals aged 16–20, with test positivity for females (65%) higher than for males (57%). Although a greater absolute number of males were rifampicin resistant, a greater proportion of females (11.4%) were rifampicin resistant as compared to males (9.3%). In the multivariate model, history of previous treatment, age less than 30, testing in the Yangon region, and female sex were significantly positively associated with rifampicin resistance after adjusting for HIV status and year test was performed. Conclusions: Our results indicate that young adults were more likely to test positive for TB and be identified as rifampicin resistant compared to older adults.


  • Open Access

    Rapid Detection of Extensively Drug-Resistant Tuberculosis in Clinical Samples Using a Novel Tabletop Platform: Protocol for a Prospective Clinical Study

    by Naomi Hillery, Marva Seifert, Donald G Catanzaro, Symone McKinnon, Rebecca E Colman, Peter G Chiles, Dumitru Chesov, Nelly Ciobanu, Christopher Hagan, Valeriu Crudu, et al.

    Background: The lack of accurate and efficient diagnostic devices for extensively drug-resistant tuberculosis (XDR-TB) makes it a severe threat to global public health. A prospective clinical study in an intended-use cohort was designed to evaluate the Akonni Biosystems XDR-TB TruArray and lateral flow cell (XDR-LFC) to address this gap in tuberculosis diagnostics. Objective: This paper presents the protocol for a study that aims to document the conceptualization and design of this evaluation method for early dissemination while data collection and analysis are ongoing. Methods: The clinical study was conducted in three phases. The first phase was to observe changes in bacterial load and culture positivity in patient sputa over time and better understand the diversity of prospective clinical samples. The second phase was to prospectively collect clinical samples for sensitivity and specificity testing of the Akonni Biosystems XDR-LFC device. Lastly, the third phase was to explore the anti-TB drug concentrations in serum throughout the drug-resistant tuberculosis treatment. Results: The methodology described includes the study design, laboratory sample handling, data collection, and the protection elements of human subjects of this clinical study to evaluate a potential new XDR-TB diagnostic device. A total of 664 participants were enrolled across the three phases. The implemented complex systems facilitated a thorough clinical data collection for an objective evaluation of the device. The study is closed to recruitment. The follow-up data collection and analysis are in progress. Conclusions: This paper outlined a prospective cohort study protocol to evaluate a rapid XDR-TB detection device, which may be informative for other researchers with similar goals. International Registered Report Identifier (IRRID): DERR1-10.2196/26748